Rubius Therapeutics went public in 2018 at a $2 billion valuation — the largest biotech stock market debut at that time. On Wednesday, the company — battered down to a market value of $15 million — said it was shutting down and liquidating all of its remaining assets.
The official end of Rubius marks one of biotech’s highest-profile flameouts. It’s also the unsurprising result of a particularly ignominious biotech financing trend: venture capitalists and their investment bankers foisting ultra-risky startups with zero clinical trial data onto the public markets.
The risk shifting has not worked out well for investors. Rubius shares have lost 99% of their value since its IPO in July 2018. Five other preclinical biotech IPOs went public around the same time as Rubius. Collectively, their stocks are down 84%.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect